DRG1: A Potential Drug Target for NPCs (G4733)

Target Name: DRG1

NCBI ID: G4733

DRG1

DRG1: A Potential Drug Target for NPCs

DRG1, also known as Neural precursor cell expressed, developmentally down-regulated 3 (NPC-DRG1), is a protein that is expressed in neural precursor cells (NPCs) and is downregulated during development. NPCs are a type of stem cell that give rise to neurons and other nervous system cells.

DRG1 is a transmembrane protein that is characterized by its extracellular domain, which is composed of a catalytic active site and a transmembrane region. The catalytic active site is responsible for the protein's catalytic activity, while the transmembrane region is responsible for its ability to interact with other proteins and molecules.

DRG1 is expressed in NPCs, which are a type of stem cell that give rise to neurons and other nervous system cells. NPCs are found in a variety of tissues throughout the body, including the brain, spinal cord, and peripheral nervous system. They are responsible for the production and maintenance of neural tissue, including neurons and glial cells.

DRG1 is downregulated during development, which is a critical time for the formation and maturation of NPCs. During development, NPCs are subject to a number of regulatory interactions that are aimed at promoting their proliferation, differentiation, and survival. However, one of the key challenges that NPCs face during development is the regulation of their gene expression.

DRG1 is a key regulator of NPC gene expression. It is part of a complex that is responsible for the negative regulation of NPC gene expression. This means that when DRG1 is activated, it can repress the activity of genes that are involved in NPC development and differentiation.

DRG1 is also involved in the regulation of cell signaling pathways that are important for NPC survival and proliferation. For example, it is involved in the regulation of the Wnt signaling pathway, which is a critical pathway for NPC survival and proliferation.

DRG1 is a potential drug target because of its involvement in the regulation of NPC development and survival. NPCs are a key cell type that give rise to many different types of nervous system cells, including neurons and glial cells. They are also involved in the production and maintenance of neural tissue, which is critical for the functioning of many different organs and systems.

DRG1 is downregulated during development, which is a critical time for the formation and maturation of NPCs. This suggests that it may be an attractive target for drugs that are aimed at promoting NPC survival and proliferation. Additionally, its involvement in the regulation of cell signaling pathways that are important for NPC survival and proliferation makes it a potential candidate for drugs that are aimed at modulating these pathways.

In conclusion, DRG1 is a protein that is expressed in NPCs and is downregulated during development. It is involved in the regulation of NPC gene expression and in the regulation of cell signaling pathways that are important for NPC survival and proliferation. As such, it is a potential drug target that could be aimed at modulating NPC development and differentiation. Further research is needed to fully understand the role of DRG1 in NPC biology and its potential as a drug target.

Protein Name: Developmentally Regulated GTP Binding Protein 1

Functions: Catalyzes the conversion of GTP to GDP through hydrolysis of the gamma-phosphate bond in GTP (PubMed:29915238, PubMed:23711155). Appears to have an intrinsic GTPase activity that is stimulated by ZC3H15/DFRP1 binding likely by increasing the affinity for the potassium ions (PubMed:23711155). When hydroxylated at C-3 of 'Lys-22' by JMJD7, may bind to RNA and play a role in translation (PubMed:19819225, PubMed:29915238). Binds to microtubules and promotes microtubule polymerization and stability that are required for mitotic spindle assembly during prophase to anaphase transition. GTPase activity is not necessary for these microtubule-related functions (PubMed:28855639)

The "DRG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DRG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets